Government · 1 deal
Vaxxas from the US Biomedical Advanced Research and Development Authority
Disclosed deals
Every published round Vaxxas from the US Biomedical Advanced Research and Development Authority took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| Vaxxas | Grant | 14 Jan 2025 | $3.2m | Lead | Business News Australia, Brandon BioCatalyst (18 Feb 2025), Brandon Capital (18 Feb 2025), @AuManufacturing (23 Jan 2025), @AuManufacturing (20 Jan 2025), Brandon BioCatalyst (14 Jan 2025), Brandon Capital (14 Jan 2025) |
Portfolio
Companies Vaxxas from the US Biomedical Advanced Research and Development Authority has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| Vaxxas | Biotech/MedTech company | 14 Jan 2025, Grant | 1 | 1 |
Funds
Fund closes reported for Vaxxas from the US Biomedical Advanced Research and Development Authority, as distinct from the investments it has made.
Portfolio companies acquired
Companies Vaxxas from the US Biomedical Advanced Research and Development Authority has backed that another company then bought. An exit for the holding, not a deal Vaxxas from the US Biomedical Advanced Research and Development Authority did.
People
Coverage
Stories naming Vaxxas from the US Biomedical Advanced Research and Development Authority. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
No coverage collected yet.